SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery Mar 31, 2026 6:00 AM Eastern Daylight Time SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc.(NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a publicationin Clinical Cancer Research showing that Signatera was able to identify older women with early-stage ER+/HER2- breast cancer who can be managed with primary endocrine therapy (pE ...